Articles - Tagged as 'ZIKAlliance'

Within the Zika virus (ZIKV) research community, a new and remarkable kind of collaboration is taking place

Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia. A commentary from the authors.

Pettersson et al provide a short commentary on their research article Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia published in Emerging Microbes & Infections in May 2018. This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under ZIKAlliance Grant Agreement no. 734548 and ZikaPLAN Grant Agreement no. 734584.

ZIKAlliance’s Clinical Meeting in Cuba 12-14 August, 2017

Successful technology transfer of a Zika vaccine developed by Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS) to Chongqing Zhifei Biological Products Co., Ltd.

Institut Pasteur Shanghai-Chinese Academy of Sciences (IPS-CAS), a partner of the ZIKAlliance consortium, announced that it has entered into a collaborative research agreement with Chongqing Zhifei Biological Products Stock Co., Ltd. (Zhifei) for the clinical studies and commercialization of a recombinant Zika virus subunit vaccine developed by IPS-CAS.

Risk of microcephaly after Zika virus infection in Brazil, 2015 to 2016

The key message from this study is that the large uncertainty around the risk estimate needs to be further investigated because of a) the possible existence of co-factors that are yet to be validated, b) the assumptions that the authors needed to make in the absence of good data for the proportion of women who were infected during pregnancy.

Study of volunteer blood donors in Martinique provides new information about Zika virus infection

This pioneering study provides a precise follow-up of incident cases and seroprevalence in blood donors, and it also provides important insights into the management of blood donations during ZIKV outbreaks and into the natural history of ZIKV infection in adults. It suggests that the study of blood donors during outbreaks of emerging pathogens has become a key element of epidemiological surveillance.

Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses

A study performed by the Institut National de la Santé et de la Recherche Médicale (INSERM) team of Dr Ali Amara (U944, Paris, France) and published in Cell Reports sheds new light on the mechanisms allowing ZIKV to infect cells within the human nervous system. Amara et al. showed that the protein Axl is expressed in a number of brain glial cells and that the entry of ZIKV into these cells requires another protein, Gas6, to act as a bridge between the ZIKV particles and the glial cells.